Clinigen Group PLC (LON:CLIN)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $931.51 and traded as low as $870.00. Clinigen Group shares last traded at $875.00, with a volume of 97,823 shares trading hands.
Several equities analysts have recently commented on the company. Peel Hunt reaffirmed a “buy” rating and issued a GBX 1,280 ($16.73) price target on shares of Clinigen Group in a research note on Tuesday, October 15th. Liberum Capital reissued a “hold” rating on shares of Clinigen Group in a research report on Friday, November 15th. Finally, Peel Hunt restated a “buy” rating on shares of Clinigen Group in a report on Monday, November 4th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Clinigen Group currently has a consensus rating of “Buy” and an average price target of GBX 1,295 ($16.92).
The business’s 50 day moving average price is GBX 838.87 and its 200-day moving average price is GBX 928.75. The company has a debt-to-equity ratio of 76.62, a quick ratio of 0.67 and a current ratio of 0.95. The firm has a market capitalization of $1.14 billion and a PE ratio of 213.88.
In related news, insider Nick Keher bought 3,900 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was purchased at an average price of GBX 893 ($11.67) per share, for a total transaction of £34,827 ($45,507.64).
Clinigen Group Company Profile (LON:CLIN)
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Read More: What is Cost of Capital?
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.